The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

In late 2021, Pfizer (PFE-0.21%) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine. It followed that success with the launch ...

Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high. Read more on PFE stock here.

No doubt, Pfizer (PFE) is one of 2021’s out-and-out success stories. The pharma giant has posted year-to-date gains of a remarkable 72%, and the company – and investors – have Covid-19 to ...

Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Drug giant Pfizer PFE is trading quite cheap after its stock took a beating last year once the pandemic ended. The stock is trading at a discount to the industry and is also trading below its 5 ...